Respiratory Syncytial Virus Vaccine (Abrysvo; Pfizer Inc.) for Prevention of Respiratory Syncytial Virus Disease in Infants Through Maternal Immunization

Abrysvo (respiratory syncytial virus vaccine; Pfizer Inc.) is a vaccine indicated for active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age.